Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

Trial Profile

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Adalimumab
  • Indications Myocarditis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms AMiRA
  • Most Recent Events

    • 06 Dec 2019 Planned primary completion date changed from 1 Jun 2021 to 1 Jul 2021.
    • 06 Dec 2019 Status changed from not yet recruiting to recruiting.
    • 14 May 2019 Planned initiation date changed from 1 Feb 2019 to 1 Jun 2019.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top